Health Impact News Editor Comments
The average chemotherapy cancer drug costs $10,000.00 per month, and only extends a patient’s life by an average of 42 days. (See: Doctors Expose Cancer Drugs Scandal.)
The Milwaukee Journal Sentinel is reporting that over the past 10 years, the FDA has approved 54 cancer drugs with no proof they are extending lives. They report that the FDA does not even require drug companies to prove their drugs extend lives:
Instead, the agency approved the drugs based on surrogate measures, such as a tumor shrinking, rather than the gold standard and most reliable measure of cancer research, patients actually surviving longer. The problem is cancer is complicated — a tumor might stop growing or shrink in one spot, then reappear somewhere else, or even in multiple places.So just remember these facts the next time you take out your wallet or checkbook to donate money to your favorite cancer charity, which pays for the research for these worthless drugs.
FDA approves cancer drugs without proof they’re extending livesBy The Journal Sentinel
For decades, researchers have focused ondeveloping new cancer drugs that save lives or improve the quality of life. But when the U.S. Food and Drug Administration allowed Inlyta, a $10,000 a month drug, on the market in 2012, there was no proof that it did either.
Inlyta is not an exception to the rule.
A Milwaukee Journal Sentinel/MedPage Today analysis of 54 new cancer drugs found that over the last decade the FDA allowed 74% of them on the market without proof that they extended life. Seldom was there proof of improved quality of life, either.
Nor has the FDA demanded companies provide such evidence.
Read the full article here.
We Lost the War on Cancer – Review of Alternative Cancer Therapies
The cancer industry is probably the most prosperous business in the United States. In 2014, there will be an estimated 1,665,540 new cancer cases diagnosed and 585,720 cancer deaths in the US. $6 billion of tax-payer funds are cycled through various federal agencies for cancer research, such as the National Cancer Institute (NCI). The NCI states that the medical costs of cancer care are $125 billion, with a projected 39 percent increase to $173 billion by 2020.
The simple fact is that the cancer industry employs too many people and produces too much income to allow a cure to be found. All of the current research on cancer drugs is based on the premise that the cancer market will grow, not shrink.
John Thomas explains to us why the current cancer industry prospers while treating cancer, but cannot afford to cure it in Part I. In Part II, he surveys the various alternative cancer therapies that have been proven effective, but that are not approved by the FDA.